RCS - Ondine Biomedical - UK Axes Financial support for AMR Fleming Fund

Ondine BiomedicalAnnouncement

Mon 09:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250721:nRSU8284Ra&default-theme=true

RNS Number : 8284R  Ondine Biomedical Inc.  21 July 2025

21 July
2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

UK Axes Financial support for AMR Fleming Fund

UK Decision to Cancel Fleming Fund Increases Urgency for Innovative
Antimicrobial Solutions; Ondine Biomedical Poised to Lead Fight Against
Superbugs

Ondine Biomedical Inc. (AIM: OBI). The UK government's decision to cancel the
Fleming Fund - a cornerstone initiative in the global fight against
antimicrobial resistance (AMR) - comes at a time when new projections point to
an escalating global crisis, threatening millions of lives and the world
economy. With models now suggesting drug-resistant infections will cost nearly
$2 trillion annually by 2050, Ondine Biomedical's advanced photodisinfection
platform stands ready to address the widening gap in infection control and
treatment.

The Fleming Fund had played a crucial role in supporting AMR surveillance and
stewardship in low - and middle - Income countries, delivering early warnings
and enabling coordinated responses. Its cancellation, leaves a dangerous void
in the global health security net, as both The Guardian and leading experts
warn of millions more deaths if resistant infections continue to rise
unchecked.

The Cost of Inaction

Recent research by the Center for Global Development reveals the true
consequences of AMR: drug-resistant infections already cost twice as much to
treat as non-resistant infections. Without robust alternatives, the world
faces annual GDP losses of $1.7 trillion by 2050 - devastating healthcare
systems in the UK, US, and Europe most acutely.

How Ondine Biomedical's Solutions Fill the Gap

Ondine Biomedical has a platform of economical light-based technologies -
including its Steriwave™ platform - that offers an urgently needed response
to the threat of multidrug resistant infections. Unlike conventional
antibiotics, Ondine's photodisinfection uses visible red light combined with a
photosensitizer to target and destroy all bacteria, fungi and viruses -
including highly resistant "superbugs" - in minutes, without contributing to
antimicrobial resistance.

"Ondine's medical devices are engineered to prevent and treat infections in
environments where antibiotics are failing," said Carolyn Cross, CEO of Ondine
Biomedical. "As stewardship initiatives lose funding, our technologies provide
a scalable, rapid solution that reduces healthcare costs, improves outcomes,
and protects society against the rising tide of drug-resistant diseases."

Proven Impact: Saving Lives and Costs

Clinical studies show that implementing Ondine's photodisinfection technology
in surgical and ICU settings can reduce hospital-acquired infections,
translating into thousands of lives saved and millions in cost avoidance.
Hospitals adopting Ondine's platform report lower readmission rates, shorter
hospital stays, and a dramatic reduction in the need for expensive last-resort
antibiotics.

A Call for Investment in Proven Technologies

With the withdrawal of Fleming Fund resources and persistent aid cuts
globally, the need for immediate, innovative interventions is clear.
Policymakers, health systems, and philanthropists must urgently invest in
non-antibiotic infection control to safeguard healthcare infrastructure,
national security, and the world economy.

 

Enquiries:

 Ondine Biomedical Inc.                                            www.ondinebio.com (http://www.ondinebio.com/)
 Carolyn Cross, CEO                                                +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Joint Financial Adviser)
 James Harris, Richard Johnson                                     +44 (0)20 7409 3494

 Peel Hunt (Broker & Joint Financial Adviser)
 James Steel, Dr. Chris Golden                                     +44 (0)20 7418 8900

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                                  +44 (0)77 1000 5910

 

References:

·     The Guardian: "Superbugs could kill millions more and cost $2tn a
year by 2050, models show" (20 July 2025)

·      Center for Global Development: [Forecasting the Fallout: The
Economic Impacts of Antimicrobial Resistance in Humans]

·     The Times: "UK fund to fight antibiotic resistance axed in
astonishing cut" (17 July 2025)

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc., a Canadian life sciences company and CAN Health
Network member, is a leader in light-activated antimicrobial therapies
('photodisinfection') for the prevention and treatment of infections,
including those caused by multidrug-resistant organisms. Ondine has a pipeline
of investigational products, based on its proprietary photodisinfection
technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and has
regulatory approval in Canada, Australia, Mexico, and several other countries
under the name Steriwave(®). In the US, Ondine's nasal photodisinfection
therapy has been granted Qualified Infectious Disease Product designation and
Fast Track status by the FDA and is currently undergoing clinical trials for
regulatory approval. Products beyond nasal photodisinfection include therapies
for a variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns, chronic wounds, and other indications.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASELEFSEISEDW